Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy
AbstrAct
Background Trifluridine/tipiracil is an oral agent approved for the treatment of patients with metastatic colorectal cancer (mCRC). Trifluridine is an antineoplastic thymidine analogue, and tipiracil improves its bioavailability. A phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with refractory mCRC demonstrated promising efficacy results with mild toxicity profile. It is important that quality of life be preserved in patients with mCRC without compromising their prognosis. Here, we outline the TRiflUridine/tipiracil in Second-line sTudY phase II/III study (JapicCTI-173618), designed to demonstrate non-inferiority in overall survival of trifluridine/tipiracil plus bevacizumab compared with irinotecan, fluoropyrimidine and bevacizumab combination regimens as second-line treatment in patients with mCRC. Patients and methods Eligible patients have confirmed unresectable advanced or recurrent colorectal adenocarcinoma and have failed to respond to first-line oxaliplatin-based chemotherapy. A total of 524 patients are to be randomly assigned (1:1 ratio) to trifluridine/ tipiracil plus bevacizumab or irinotecan, fluoropyrimidine and bevacizumab and stratified according to RAS status (wild type vs mutant). The primary endpoint of the phase II part is disease control rate with trifluridine/tipiracil plus bevacizumab therapy. Secondary endpoints are response rate and safety with trifluridine/tipiracil plus bevacizumab therapy. In the phase III part, the primary endpoint is overall survival, and secondary endpoints include quality of life, progression-free survival, response rate, disease control rate, safety, time to treatment failure, time to post-study treatment failure and the proportion of patients receiving post-study treatment. The first patient was enrolled in October 2017 and the study is anticipated to be completed in 2022. Clinical trial registration JapicCTI-173618 (JapicCTI).
IntroduCtIon
Fluorouracil and leucovorin combined with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) plus bevacizumab is widely used as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC). 1 In Japan, the treatment of mCRC typically involves chemotherapy using oxaliplatin-based regimens as first-line treatment, with irinotecan-based regimens frequently used afterwards. [2] [3] [4] The FIRIS study showed that oral S-1 and irinotecan was non-inferior to FOLFIRI, in terms of progression-free survival (PFS), as second-line treatment for mCRC. 5 Additionally, the TRICOLORE trial showed that S-1 and irinotecan plus bevacizumab was non-inferior to FOLFOX or capecitabine/oxaliplatin plus bevacizumab as first-line treatment. 6 In the ML18147 study, 7 continuous use of bevacizumab from firstline to second-line treatment was associated with prolonged overall survival (OS). Bevacizumab therefore represents a viable treatment option even for patients with mCRC and progression after bevacizumab-combined chemotherapy as first-line treatment. The treatment aims for mCRC are typically not curative but are instead focused on prolonging survival and improving quality of life (QOL). However, treatment regimens based on irinotecan are associated with severe toxicities, which can be detrimental to the treatment objectives. 8 It is therefore clear that treatment options that preserve QOL and improve prognosis while maintaining acceptable toxicity are required for this patient population.
Trifluridine/tipiracil consists of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. Trifluridine, an antineoplastic thymidine analogue, and tipiracil, a thymidine phosphorylase inhibitor that improves the bioavailability of trifluridine, are approved as an oral combination preparation for the treatment of mCRC in the USA, Europe, and Japan. The RECOURSE global phase III study demonstrated a significant improvement in OS with trifluridine/tipiracil compared with placebo in patients with refractory colorectal cancer (median OS, 7.1 vs 5.3 months; HR 0.68; 95% CI 0.58 to 0.81, p<0.001). 9 More recently, the TERRA study demonstrated similar findings in an Asian population with mCRC (median OS, 7.8 vs 7.1 months; HR 0.79; 95% CI 0.62 to 0.99, p=0.035) as well as improved PFS (2.0 vs 1.8 months; HR 0.43; 95% CI 0.34 to 0.54, p<0.001). 10 In both studies, the most frequent adverse event (AE) of grade 3 or higher was neutropenia, occurring in 38.0% and 20.3% of patients receiving trifluridine/tipiracil in the RECOURSE and TERRA studies, respectively.
In a xenograft model of human CRC, trifluridine/ tipiracil in combination with bevacizumab demonstrated synergistic activity. 11 The C-TASK FORCE phase I/II study of trifluridine/tipiracil plus bevacizumab in patients with mCRC unresponsive to standard treatment demonstrated the potential of this regimen to extend PFS (5.6 months, 95% CI 3.4 to 7.6 by investigator assessment) and median survival time (MST; 11.4 months, 95% CI 7.6 to 13.9) with acceptable toxicity, although 68% of patients reported neutropenia as a treatment-emergent AE of grade 3 or worse. 12 However, the magnitude of the antitumour effect and severity of AEs for trifluridine/tipiracil plus bevacizumab as second-line treatment in patients with mCRC remain unclear.
Therefore, the purpose of this phase II/III TRiflUridine/tipiracil in Second-line sTudY (TRUSTY) is to demonstrate the non-inferiority in terms of OS of trifluridine/tipiracil plus bevacizumab compared with FOLFIRI plus bevacizumab or S-1 and irinotecan plus bevacizumab regimens as second-line treatment in patients with mCRC. of S-1 40 mg/m 2 twice daily from day 1 to day 14 in a 21-day cycle) or (3) S-1 and irinotecan plus bevacizumab therapy with a 4-week cycle (bevacizumab 5 mg/kg and irinotecan 100 mg/m 2 by intravenous infusion on days 1 and 15, and oral administration of S-1 40 mg/m 2 twice daily from day 1 to day 14 in a 28-day cycle). Eligible patients are subsequently randomised at a ratio of 1:1 to either Group A or to the trifluridine/tipiracil plus bevacizumab (Group B) treatment arm (bevacizumab 5 mg/kg by intravenous infusion on days 1 and 15, plus oral administration of trifluridine/tipiracil 35 mg/m 2 twice daily on days 1-5 and 8-12 in a 28-day cycle). For all regimens, administration of chemotherapy is repeated until any study discontinuation criterion is met. For randomisation, a minimisation method is used after patient stratification according to RAS status (wild type vs mutant). The primary lesion (left sided vs right sided) and, for patients with wildtype RAS status, first-line treatment with a molecular-targeted drug (bevacizumab vs antiepidermal growth factor receptor antibody) are used as stratification factors. The phase II part of the study will analyse safety and efficacy data in the first 50 patients in Group B who become evaluable for tumour response based on the Response Evaluation Criteria in Solid Tumours (RECIST) criteria. These data will be assessed by an independent data monitoring committee who will establish the criteria for the progression of patients to phase III.
This study is being conducted in accordance with the guidelines for Good Clinical Practice of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, as well as the ethical guidelines for medical and health research involving human subjects. Patients will provide written informed consent prior to participation. This study is registered with the Japan Pharmaceutical Information Center (registration number JapicCTI-173618).
Patients
Patients with confirmed, unresectable, advanced or recurrent colorectal adenocarcinoma and known RAS gene mutation status by a validated testing method, who have failed first-line oxaliplatin-based chemotherapy, are eligible for inclusion. Additional eligibility criteria are listed in box 1. Discontinuation criteria include progressive disease based on RECIST, clinical progression, patient decision or ineligibility or investigator judgement based on AEs or other reason.
Endpoints and assessments
The primary endpoint of the phase II study is disease control rate (DCR) with trifluridine/tipiracil plus bevacizumab therapy. The secondary endpoints are response rate (RR) and safety with trifluridine/tipiracil plus bevacizumab therapy. In the phase III study, the primary endpoint is OS, and secondary endpoints include QOL, PFS, RR, DCR, safety, time to treatment failure, time to post-study treatment failure (defined as the period from the date of enrolment to the date of discontinuation of 
statistical analysis
Based on previous studies 5 15 and improved treatment options for patients with mCRC, the MST is assumed to be 19 months for both groups. The lower point estimate of MST with Group B therapy is considered acceptable for maintaining QOL, and the acceptable non-inferiority margin for the HR is specified as 1.33 based on the value for Group A therapy. Consequently, with a one-sided significance level of 2.5% and a power of 80%, and with a 24-month enrolment period and a 30-month follow-up period after last patient enrolment, a sample size of at least 499 patients was deemed necessary. Assuming a discontinuation rate of approximately 5%, the target number of patients was set at 524. If non-inferiority with a margin of 1.33 (as HR) is demonstrated, superiority and the non-inferiority hypothesis with a margin of 1.25 (as HR) will be evaluated.
Primary analysis in the phase III study will be performed in the full-analysis set, defined as all randomised patients except those with serious protocol violations or who have withdrawn consent to participate. The safety analysis set will comprise all patients in the full analysis set who receive at least one dose of study drug in their assigned treatment group. The Kaplan-Meier method will be used to describe OS, with Cox proportional hazard modelling used to calculate HRs and two-sided 95% CIs.
ConClusIon
TRUSTY is the first phase II/III study to evaluate the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab compared with irinotecan-based chemotherapy as second-line treatment in patients with mCRC. This study, to be conducted at 63 study sites in Japan, commenced in October 2017 and is expected to complete in March 2022. We anticipate that the findings will contribute to establishing the safety and efficacy of the study treatment in this patient population.
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